Phase II study of nivolumab (anti-PD1), tadalafil, and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.
2020
TPS4656Background: Treatment options for advanced hepatocellular carcinoma (HCC) and liver dominant metastatic disease from colorectal or pancreatic cancers are limited with poor overall survival. ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI